The company said that the facility has been designed for the supply of late-phase clinical trial tablet and capsule products, and will be capable of handling batch sizes of up to 120kg. It will consist of a new pilot plant and equipment designed to contain high potency products.
Process trains will be scalable to commercial lines, offering clients the ability to produce phase 3 and commercial product in the same location.
Wes Wheeler, president and CEO of Patheon, said: “We currently provide our customers with solid dose Phase 3 and commercial supply from our facilities in North America. With this expansion we will offer the same services in Europe by the end of 2010. The investment reinforces our commitment to provide our customers with a full range of product development services – from pre-clinical through late phase stages, on to commercialisation.”